BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/22/2023 4:14:47 AM | Browse: 498 | Download: 1374
Publication Name World Journal of Clinical Oncology
Manuscript ID 86914
Country United States
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Autoimmune diabetes from pembrolizumab: A case report and review of literature
Manuscript Source Unsolicited Manuscript
All Author List Hardikkumar Bhanderi, Farhan Khalid, Zubair Hassan Bodla, Tayyeb Muhammad, Doantrang Du and Trishala Meghal
ORCID
Author(s) ORCID Number
Hardikkumar Bhanderi http://orcid.org/0000-0002-7939-0958
Funding Agency and Grant Number
Corresponding Author Hardikkumar Bhanderi, MD, Staff Physician, Internal Medicine, Monmouth Medical Center, 300 2nd Avenue, Long branch, NJ 07740, United States. dr.hardikkumar.bhanderi@gmail.com
Key Words Pembrolizumab; Breast cancer; Autoimmune diabetes; Keytruda; Immunotherapy; Case report
Core Tip Our review highlights an important and rare adverse effect of Pembrolizumab. We have also reviewed the number of cycles patients were treated with Keytruda before the onset of diabetes. Clinicians should be watchful for the signs and symptoms. Early discontinuation of immunotherapy is needed to prevent significant morbidity and mortality.
Publish Date 2023-11-22 04:14
Citation Bhanderi H, Khalid F, Bodla ZH, Muhammad T, Du D, Meghal T. Autoimmune diabetes from pembrolizumab: A case report and review of literature. World J Clin Oncol 2023; 14(11): 535-543
URL https://www.wjgnet.com/2218-4333/full/v14/i11/535.htm
DOI https://dx.doi.org/10.5306/wjco.v14.i11.535
Full Article (PDF) WJCO-14-535-with-cover.pdf
Full Article (Word) WJCO-14-535.docx